Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications
Authors:
- 28 July 2009
- journal article
- review article
- Published by Springer Nature in Diabetologia
- Vol. 52 (11) , 2251-2263
Abstract
The pattern recognition receptor or receptor for AGE (RAGE) is constitutionally expressed in a few cell types only. However in almost all cells studied so far it is induced by reactions known to initiate inflammation. Its biological activity seems to be mainly dependent on the presence of its various ligands, including AGE, S100-calcium binding protein/calgranulins, high-mobility group protein 1, amyloid-β-peptides and the family of β-sheet fibrils, all known to be elevated in chronic metabolic, malignant and inflammatory diseases. The RAGE pathway interacts with cytokine-, lipopolysaccharide-, oxidised LDL- and glucose-triggered cellular reactions by turning a short-lasting inflammatory response into a sustained change of cellular function driven by perpetuated activation of the proinflammatory transcription factor, nuclear factor kappa-B. RAGE-mediated persistent cell activation is of pivotal importance in various experimental and clinical settings, including diabetes and its complications, neurodegeneration, ageing, tumour growth, and autoimmune and infectious inflammatory disease. Due to RAGE’s central role in maintaining perpetuated cell activation, various therapeutic attempts to block RAGE or its ligands are currently under investigation. Despite broad experimental evidence for the role of RAGE in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE × ligand interaction in chronic diseases.Keywords
This publication has 112 references indexed in Scilit:
- Binding of S100 proteins to RAGE: An updateBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Receptor for AGE (RAGE) and its ligands—cast into leading roles in diabetes and the inflammatory responseJournal of Molecular Medicine, 2009
- Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationAnnals of Medicine, 2009
- Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42Journal of Biological Chemistry, 2008
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetesMicrovascular Research, 2008
- RAGE signaling sustains inflammation and promotes tumor developmentJournal of Experimental Medicine, 2008
- The Extracellular Region of the Receptor for Advanced Glycation End Products Is Composed of Two Independent Structural UnitsBiochemistry, 2007
- A novel pathway of HMGB1‐mediated inflammatory cell recruitment that requires Mac‐1‐integrinThe EMBO Journal, 2007
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003
- Advanced oxidation protein products as a novel marker of oxidative stress in uremiaKidney International, 1996